Gardos channel

Gardos channel

A cell membrane pore that regulates intracellular volume with a pump that forces potassium ions out of the cell. The pump is activated by calcium ions.
References in periodicals archive ?
The drug, known as ICA-17043, is part of new class known as Gardos channel inhibitors.
Efficacy and Safety of the Gardos Channel Inhibitor, ICA-17043, in Patients with Sickle Cell Anemia [Abstract 103]
The drug, ICA- 17043 (bis(4-fluorophenyl)phenyl acetamide), is a member of a new class of drugs called Gardos Channel Inhibitors.
Abstract #685 - A 48-Week Open-Label Study of Senicapoc (ICA-17043), a Gardos Channel Blocker, in Patients with Sickle Cell Disease
Senicapoc targets a particular potassium channel, called the Gardos channel, that is located on the membrane of red blood cells.
By blocking the Gardos channel, ICA-17043 helps to prevent the dehydration of sickle red blood cells and the attendant rise of intracellular hemoglobin concentration that plays an important pathophysiologic role in sickle cell disease.
Activation of the Gardos channel has been linked to the dehydration of red blood cells, which is an integral part of the pathophysiology of sickle cell disease.
ICA-17043 targets a particular potassium channel, called the Gardos channel, that is located on the membrane of red blood cells.
The rationale for using clotrimazole to treat sickle cell anemia is based on its ability to prevent the dehydration of red blood cells by blocking a specific ion transport pathway, known as the Gardos channel, and thereby inhibiting the loss of cellular potassium The dehydration is an important factor in the characteristic sickling of red blood cells associated with the disease.
It is our present intent, subject to further input from the DMC, to complete the modified ASSERT trial as we seek to establish the benefit of this novel Gardos channel inhibitor, when used in combination with hydroxyurea, to reduce the rate of vaso-occlusive crises in patients with sickle cell disease.
We look forward to the completion of enrollment in this pivotal Phase III trial studying the effect of ICA-17043, a novel Gardos channel inhibitor, on the rate of vaso-occlusive crisis in patients with sickle cell disease.
Supporting the findings of our Phase II study, these results suggest that block of the Gardos channel with ICA-17043 results in a sustained reduction in hemolysis and improvement in anemia in patients with sickle cell anemia.